Fosl1: friend or foe?

Shruti Bhargava; Joachim Jankowski

doi:10.1016/j.kint.2022.12.019

Fosl1: friend or foe?

Kidney Int. 2023 Apr;103(4):656-658. doi: 10.1016/j.kint.2022.12.019.

Authors

Shruti Bhargava¹, Joachim Jankowski²

Affiliations

¹ Institute of Molecular Cardiovascular Research, Medical Faculty, RWTH Aachen University, Aachen, Germany.
² Institute of Molecular Cardiovascular Research, Medical Faculty, RWTH Aachen University, Aachen, Germany; Experimental Vascular Pathology, Cardiovascular Research Institute Maastricht (CARIM), University of Maastricht, Maastricht, the Netherlands; Aachen Maastricht Institute for Cardiorenal Research (AMICARE), RWTH Aachen University, Aachen, Germany. Electronic address: jjankowski@ukaachen.de.

PMID: 36948764
DOI: 10.1016/j.kint.2022.12.019

Abstract

Fos-like antigen 1 (Fosl1) is a protein that belongs to the Fos family of transcription factors. Fosl1 has an impact on (i) carcinogenesis, (ii) acute kidney injury, and (iii) fibroblast growth factor expression. Recently, the nephroprotective effect of Fosl1 by the preservation of Klotho expression was recently identified. The identification of a link between Fosl1 and Klotho expression provides an entirely new field of nephroprotection.

Publication types

Comment